Digest Network Come funziona
Network
/
Società
Co
Non verificato

Contineum Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

30 comunicati stampa

Guarda tutti i comunicati
13/03/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/03/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/03/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Finanza
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/12/2025
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/12/2025
Finanza
Biotecnologia
Psichiatria
Salute
Farmaceutica
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/11/2025
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0